Diagnostic antibodies and antigens for multiple disease testing: thioredoxin reductase (TrxR), Amphetamines (AMP), Buprenorphine (Bup), Benzoditezite (BZO), Synthetic cannabinoid (K2), 3,4-Methylenedioxymethamphetamine (MDMA)
Thioredoxin (Trx) and thioredoxin reductase (TrxR) plus NADPH, comprising the thioredoxin system, has a large number of functions in DNA synthesis, defense against oxidative stress and apoptosis or redox signaling with reference to many diseases such as cancer, viral disease, ischaemia– reperfusion injury, cardiac conditions, aging, premature birth and newborn physiology. GENEMEDI produces core diagnostic ingredients such as thioredoxin reductase and so on to test multiple disorders using ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT Kit.
Classification:
TrxR
AMP
Bup
BZO
K2
MDMA
thioredoxin reductase (TrxR)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-h-TrxR | Human | thioredoxin reductase (TrxR) | cancer, viral disease, ischaemia– reperfusion injury, cardiac conditions, aging, premature birth | GMP-h-TrxR-Ag01: Recombinant human TrxR Protein |
thioredoxin reductase (TrxR) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays as control material in TrxR level test of Multiple disease(cancer, viral disease, ischaemia– reperfusion injury, cardiac conditions, aging, premature birth) and related syndrome evaluation. | GMP-h-TrxR-Ab01 GMP-h-TrxR-Ab02: Anti-human TrxR mouse monoclonal antibody(mAb) |
Human thioredoxin reductase (TrxR) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other thioredoxin reductase (TrxR) antibodies in TrxR level test of Multiple disease (cancer, viral disease, ischaemia– reperfusion injury, cardiac conditions, aging, premature birth) and related syndrome evaluation. |
Amphetamines (AMP)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-SMT-223 | Human | Amphetamines (AMP) | ADHD, narcolepsy | GMP-SMT-223-Ag01: BSA-Amphetamines (AMP) GMP-SMT-223-Ag02: OVA-Amphetamines (AMP) | Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-Amphetamines (AMP), Amphetamines (AMP) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in AMP level test of Multiple disease (ADHD, narcolepsy) and related syndrome evaluation. | GMP-SMT-223-Ab01: Anti-Amphetamines (AMP) mouse monoclonal antibody(mAb) GMP-SMT-223-Ab02: Anti-Amphetamines (AMP) human monoclonal antibody(mAb) | Amphetamines (AMP) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Amphetamines (AMP) antibodies in AMP level test of Multiple disease (ADHD, narcolepsy) and related syndrome evaluation. |
Buprenorphine (Bup)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-SMT-225 | Human | Buprenorphine (Bup) | GMP-SMT-225-Ag01: BSA-Buprenorphine (Bup) GMP-SMT-225-Ag02: OVA-Buprenorphine (Bup) | Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-Buprenorphine (Bup), Buprenorphine (Bup) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in Bup level test of Multiple disease and related syndrome evaluation. | GMP-SMT-225-Ab01: Anti-Buprenorphine (Bup) mouse monoclonal antibody(mAb) GMP-SMT-225-Ab02: Anti-Buprenorphine (Bup) human monoclonal antibody(mAb) | Buprenorphine (Bup) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Buprenorphine (Bup) antibodies in Bup level test of Multiple disease and related syndrome evaluation. |
Benzoditezite (BZO)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-SMT-226 | Human | Benzoditezite (BZO) | GMP-SMT-226-Ag01: BSA-Benzoditezite (BZO) GMP-SMT-226-Ag02: OVA-Benzoditezite (BZO) | Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-Benzoditezite (BZO), Benzoditezite (BZO) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in BZO level test of Multiple disease and related syndrome evaluation. | GMP-SMT-226-Ab01: Anti-Benzoditezite (BZO) mouse monoclonal antibody(mAb) GMP-SMT-226-Ab02: Anti-Benzoditezite (BZO) human monoclonal antibody(mAb) | Benzoditezite (BZO) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Benzoditezite (BZO) antibodies in BZO level test of Multiple disease and related syndrome evaluation. |
Synthetic cannabinoid (K2)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-SMT-233 | Human | Synthetic cannabinoid (K2) | GMP-SMT-233-Ag01: BSA-Synthetic cannabinoid (K2) GMP-SMT-233-Ag02: OVA-Synthetic cannabinoid (K2) | Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-Synthetic cannabinoid (K2), Synthetic cannabinoid (K2) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in K2 level test of Multiple disease and related syndrome evaluation. | GMP-SMT-233-Ab01: Anti-Synthetic cannabinoid (K2) mouse monoclonal antibody(mAb) GMP-SMT-233-Ab02: Anti-Synthetic cannabinoid (K2) human monoclonal antibody(mAb) | Synthetic cannabinoid (K2) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Synthetic cannabinoid (K2) antibodies in K2 level test of Multiple disease and related syndrome evaluation. |
3,4-Methylenedioxymethamphetamine (MDMA)
Cat No. | Species | Biomarker | Disease | Cat No.of Antigen | Bioactivity validation of Antigen | Cat No.of Antibodies | Bioactivity validation of Antibodies | Order |
GMP-SMT-235 | Human | 3,4-Methylenedioxymethamphetamine (MDMA) | GMP-SMT-235-Ag01: BSA-3,4-Methylenedioxymethamphetamine (MDMA) GMP-SMT-235-Ag02: OVA-3,4-Methylenedioxymethamphetamine (MDMA) | Competitive immunoassay-validated hapten-carrier conjugates BSA-&OVA-3,4-Methylenedioxymethamphetamine (MDMA), 3,4-Methylenedioxymethamphetamine (MDMA) antibodies binding, Immunogen in Competitive immunoassay validation, Elisa, lateral-flow tests,and other immunoassays as control material in MDMA level test of Multiple disease and related syndrome evaluation. | GMP-SMT-235-Ab01: Anti-3,4-Methylenedioxymethamphetamine (MDMA) mouse monoclonal antibody(mAb) GMP-SMT-235-Ab02: Anti-3,4-Methylenedioxymethamphetamine (MDMA) human monoclonal antibody(mAb) | 3,4-Methylenedioxymethamphetamine (MDMA) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other 3,4-Methylenedioxymethamphetamine (MDMA) antibodies in MDMA level test of Multiple disease and related syndrome evaluation. |